Mature results of a randomized phase II multicenter study of exemestane versus tamoxifen as first-line hormone therapy for postmenopausal women with metastatic breast cancer

Chan, 1999, Prospective randomized trial of docetaxel versus doxorubicin in patients with metastatic breast cancer, J Clin Oncol, 17, 2341, 10.1200/JCO.1999.17.8.2341

Mouridsen, 2001, Final survival analysis of the double-blind randomized multinational phase III trial of letrozole (Femara®) compared to tamoxifen as first-line hormonal therapy for advanced breast cancer, Breast Cancer Res Treat, 69, 211

Klijn, 2000, Combined treatment with buserelin and tamoxifen in premenopausal metastatic breast cancer: a randomized study, J Natl Cancer Inst, 92, 903, 10.1093/jnci/92.11.903

Paridaens, 1980, Clinical significance of the quantitative assessment of estrogen receptors in advanced breast cancer, Cancer, 46, 2889, 10.1002/1097-0142(19801215)46:12+<2889::AID-CNCR2820461430>3.0.CO;2-4

Demers, 1994, Effects of fadrozole and letrozole on the inhibition of aromatase activity in breast cancer patients, Breast Cancer Res Treat, 30, 95, 10.1007/BF00682744

Geisler, 1996, Influence of anastrozole (Arimidex), a selective, non-steroidal aromatase inhibitor, on in vivo aromatisation and plasma oestrogen levels in postmenopausal women with breast cancer, Br J Cancer, 74, 1286, 10.1038/bjc.1996.531

Paridaens, 1998, Safety, activity and estrogen inhibition by exemestane in postmenopausal women with advanced breast cancer: a phase I study, Anticancer Drugs, 9, 675, 10.1097/00001813-199809000-00002

Bonneterre, 2000, Anastrozole versus tamoxifen as first-line therapy for advanced breast cancer in 668 postmenopausal women: results of the Tamoxifen or Arimidex Randomized Group Efficacy and Tolerability Study, J Clin Oncol, 18, 3748, 10.1200/JCO.2000.18.22.3748

Nabhlotz, 2000, Anastrozole is superior to tamoxifen as first-line therapy for advanced breast cancer in postmenopausal women: results of a North American multicenter randomized trial, J Clin Oncol, 18, 3758, 10.1200/JCO.2000.18.22.3758

Mouridsen, 2001, Superior efficacy of letrozole versus tamoxifen as first-line therapy for postmenopausal women with advanced breast cancer: Results of a phase III study of the International Letrozole Breast Cancer Group, J Clin Oncol, 19, 2596, 10.1200/JCO.2001.19.10.2596

Dombernowsky, 1998, Letrozole, a new oral aromatase inhibitor for advanced breast cancer: double-blind randomized trial showing a dose effect and improved efficacy and tolerability compared with megestrol acetate, J Clin Oncol, 16, 453, 10.1200/JCO.1998.16.2.453

Hamilton, 1999, The third-generation non-steroidal aromatase inhibitors: a review of their clinical benefits in the second-line hormonal treatment of advanced breast cancer, Ann Oncol, 10, 377, 10.1023/A:1008368300827

Buzdar, 1998, Anastrozole versus megestrol acetate in the treatment of postmenopausal women with advanced breast carcinoma: results of a survival update based on a combined analysis of data from two mature phase III trials, Cancer, 83, 1142, 10.1002/(SICI)1097-0142(19980915)83:6<1142::AID-CNCR13>3.0.CO;2-5

Gershanovich, 1998, Letrozole, a new oral aromatase inhibitor: randomised trial comparing 2.5mg daily, 0.5mg daily and aminoglutethimide in postmenopausal women with advanced breast cancer, Ann Oncol, 9, 639, 10.1023/A:1008226721932

Buzdar, 1999, Role of aromatase inhibitors in advanced breast cancer, Endocr Relat Cancer, 6, 219, 10.1677/erc.0.0060219

Jones, 1999, Multicenter, phase II trial of exemestane as third-line hormonal therapy of postmenopausal women with metastatic breast cancer, J Clin Oncol, 17, 3418, 10.1200/JCO.1999.17.11.3418

Thürlimann, 1997, Third-line hormonal treatment with exemestane in postmenopausal patients with advanced breast cancer progressing under aminoglutethimide: a phase II multicentre multinational study, Eur J Cancer, 33, 1767, 10.1016/S0959-8049(97)00283-9

Kaufmann, 2000, Exemestane is superior to megestrol acetate following tamoxifen failure in postmenopausal women with advanced breast cancer: results of a phase III randomized double-blind trial, J Clin Oncol, 18, 1399, 10.1200/JCO.2000.18.7.1399

Lonning, 2000, Activity of exemestane in metastatic breast cancer after failure of nonsteroidal aromatase inhibitors: a phase II trial, J Clin Oncol, 18, 2234, 10.1200/JCO.2000.18.11.2234

MacDonald, 1995, Manual of Oncologic Therapeutics, 519

Miller, 1987, Reporting results of cancer treatment, Cancer, 47, 207, 10.1002/1097-0142(19810101)47:1<207::AID-CNCR2820470134>3.0.CO;2-6

Paridaens, 2000, Exemestane (Aromasin®) is active and well tolerated as first-line hormonal therapy (HT) of metastatic breast cancer (MBC) patients (pts) results of a randomised phase II trial, Proc Am Soc Clin Oncol, 19, 83a

Di Salle, 1994, Sex hormones and Antihormones in Endocrine Dependent Pathology: Basic and Clinical Aspects, 303

Miller, 2000, Anti-aromatase agents: preclinical data and neoadjuvant therapy, Clin Breast Cancer, 1, 9, 10.3816/CBC.2000.s.002

Miller, 1999, Biology of aromatase inhibitors: pharmacology/endocrinology within the breast, Endocr Relat Cancer, 6, 187, 10.1677/erc.0.0060187

Howell, 1988, The definition of the ‘no change’ category in patients treated with endocrine therapy and chemotherapy for advanced carcinoma of the breast, Eur J Cancer, 24, 1567, 10.1016/0277-5379(88)90046-6

Bernhard, 1999, Defining clinical benefit in postmenopausal patients with breast cancer under second-line endocrine treatment: does quality of life matter?, J Clin Oncol, 17, 1672, 10.1200/JCO.1999.17.6.1672